Case Report

Acute Pancreatitis in COVID-19 Patients: Two Case Reports and Review of Literature

Sreenivas Reddy Madhurantakam1, Padmakumar V Arayamparambil2, Garud Suresh Chandan3, Pooja Prathapan Sarada4

1Senior Registrar, Department of Critical Care Medicine, Fortis Hospital Bannerghatta Road, 154/9, Opp. IIM-B, Bangalore-560076, Karnataka, India
2Director & Head of the Department, Department of Critical Care Medicine, Fortis Hospital Bannerghatta Road, 154/9, Opp. IIM-B, Bangalore-560076, Karnataka, India
3Senior Consultant, Department of Critical Care Medicine, Fortis Hospital Bannerghatta Road, 154/9, Opp. IIM-B, Bangalore-560076, Karnataka, India
4Consultant, Department of Critical Care Medicine, Fortis Hospital Bannerghatta Road, 154/9, Opp. IIM-B, Bangalore-560076, Karnataka, India

Abstract: Coronavirus disease 2019 (COVID-19) is primarily a respiratory tract disease but involves other organ systems too, especially gastrointestinal system. Acute pancreatitis is one of the manifestations of COVID-19, as pancreatic gland also expresses the angiotensin-converting enzyme 2 receptors. We present two cases, where none of them presented with symptoms of pancreatitis on admission. Our first patient presented with severe acute respiratory distress syndrome secondary to COVID-19 and during her stay necrotizing pancreatitis was incidentally detected on CT scan. Our second patient presented as an acute fatty liver of pregnancy and was incidentally found to be COVID-19 positive and later developed symptoms of acute pancreatitis.

Keywords: COVID-19, Acute Pancreatitis, lipase, Necrotizing pancreatitis, SARS-CoV-2.

INTRODUCTION

The Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2) pandemic has created havoc across the globe. It’s a multisystemic disease mainly involving the upper respiratory tract system. The extrapulmonary manifestations are still not very well understood. The gastrointestinal (GI) manifestations of the COVID-19 infection include anorexia, nausea, vomiting, abdominal pain, and diarrhoea. Pancreatic gland expresses angiotensin-converting enzyme 2 (ACE-2), the proven receptor for SARS-CoV-2 cell binding. The symptoms of pancreatitis in COVID-19 patients vary from asymptomatic abnormal pancreatic enzyme elevation to necrotizing pancreatitis. However, pancreatic involvement in patients with COVID-19 is rarely reported. Here, we report two cases of acute pancreatitis with COVID-19.

CASE REPORT-1

A 48 year old, female, who was a known case of diabetes mellitus, hypertension, hypothyroidism, end stage renal disease on maintenance haemodialysis through a long term dialysis catheter and previously acquired Hepatitis C infection, presented to us with complaints of fever, giddiness and weakness for 3 days. She had also missed her regular dialysis due to fever.

Initial evaluation revealed a temperature of 101°F, blood oxygen saturation (SpO2) of 89% on 10 liter/minute of oxygen and arterial blood gas (ABG) analysis showed metabolic acidosis. Patient was tested positive for COVID-19. After the initial Non-invasive ventilation trial, she was intubated and dialysed for severe metabolic acidosis. She became hemodynamically unstable requiring vasopressors. Patient was managed with steroids, anticoagulation and prone ventilation for severe acute respiratory distress syndrome (ARDS). Antibiotics were started for suspected central line – associated bloodstream infections (CLABS). Initial blood cultures grew Candida tropicalis, endotracheal secretion culture grew Klebsiella pneumonia (ESBL+ Carbapenemase producing). Long term dialysis catheter was removed.
As the patient’s haemodynamics and oxygenation improved, she was tracheostomized and gradual weaning from the ventilator was started in the 3rd week of admission. She developed persistent non-infective diarrhoea during her stay. After 4 weeks of admission, the patient was tested negative for COVID-19 with demonstrable IgG antibody. Patient’s computed tomography (CT) abdomen showed evidence of acute/subacute necrotizing pancreatitis with peripancreatic walled-off collection (Figure-1). In view of this her serum lipase and triglycerides were sent which was 69 Units/Liter and 3.22 mmol/L respectively.

CASE REPORT-2

A 27 year old primigravida at 37 weeks of gestation was admitted with acute fatty liver of pregnancy, acute kidney injury and was incidentally detected to be COVID-19 positive. Preoperative ultrasound sonography (USG) abdomen was found to be normal. She underwent an emergency caesarean section for obstetric indication. Blood and blood products were transfused for coagulopathy. She remained stable for the next 36 hrs. On post operative day - 3, she complained of abdominal discomfort and distention. USG abdomen was done that showed edematous pancreas. Her serum amylase (363U/L) and lipase (3885U/L) were found to be elevated. Because of progressive drowsiness and worsening coagulopathy, she was intubated. CT brain showed normal study. CT abdomen showed acute interstitial edematous pancreatitis with no evidence of gallbladder sludge, stone or dilatation of main pancreatic duct or any biliary dilatation (Figure-2). She progressively became more unstable with worsening acute kidney injury associated with lactic acidosis requiring hemodialysis. Patient was found to have significant hypocalcemia with QTc >700 milliseconds requiring continuous calcium gluconate infusion. Her sensorium remained poor in spite of correcting metabolic parameters. Patient succumbed to fulminant cerebral edema on day 8 of admission.
**DISCUSSION**

COVID-19 is a multisystemic condition caused by coronavirus 2 with manifestations ranging from mild upper respiratory symptoms to cytokine storm causing severe ARDS. COVID-19 has been widely studied as a lung pathogen. However, GI association with COVID-19 has also been reported in recent studies. Studies have shown that up to 50% of COVID-19 patients develop GI symptoms of nausea, vomiting, diarrhoea and abdominal pain [1]. In a recent study, 11.4% of the patients exhibited at least one of the GI symptoms involving nausea, vomiting, or diarrhoea [2].

The pathogenesis of acute pancreatitis is multifactorial. Gallstones and alcohol being the leading cause, viruses such as mumps, Coxsackie B, measles, Epstein–Barr and hepatitis A, B, and E can also cause acute pancreatitis. There has also been few reported associations between H1N1 influenza and acute pancreatitis [3-5].

Up to 10 percent of acute pancreatitis is thought to have an infectious aetiology through an immune-mediated inflammatory response, most notably mumps and Coxsackie B viruses [6, 7].

Although viral acute pancreatitis has been described in other viral infections, pancreatic involvement in SARS-CoV-2 infection is still poorly defined. We are reporting two cases of acute pancreatitis in patients with SARS-CoV-2 infection.

ACE2 receptors does not only express in the lung alveolar type-2 (AT-2) cells but also manifests in the esophagus, small intestine, large intestine, and pancreatic islet cells [8]. Glycosylated-spike (S) protein, which is one of the structural proteins encoded by the coronavirus genome, binds to ACE2 receptor protein located on the host cell surface membrane and mediates the host cell invasion [9, 10]. High expression of ACE2 receptors in the pancreatic islet cells can cause cell damage due to COVID-19, resulting in acute pancreatitis. Direct cytopathic effects of COVID-19 or immune-mediated and indirect systemic inflammatory response could be the mechanism of pancreatic injury [11-13].

Patient-1 developed unexplained diarrhoea 2 to 3 weeks after admission and CT abdomen incidentally picked up acute pancreatitis with already established peripancreatic septated collections. In the initial weeks of admission, sedation and paralysis for severe ARDS probably masked the symptoms of acute pancreatitis. The non-specific symptoms of the patient were correlated retrospectively after CT imaging. Patient-2 developed signs and symptoms of pancreatitis with symptoms like diffuse abdominal pain and symptomatic hypocalcemia.

Since the emergence of the SARS CoV-2 pandemic in December 2019, a few studies have reported a potential pancreatic injury in association with SARS-CoV-2 infection attributed to either a direct cytopathic effect of the virus or subsequent to the associated systemic inflammatory response.

Safaa Saeed Al Mazrouei, Kataria et al., [5], in their case reports, suggested the possibility of direct causal relation between COVID-19 infection and acute pancreatitis. Antunes Meireles et al., [14] reported acalculous acute pancreatitis in a COVID-19 patient and concluded acute pancreatitis may be a manifestation of SARS-CoV-2 infection. Anand et al., [6] have reported the case of a 59-year-old female patient who was diagnosed with acute pancreatitis.
based on typical abdominal pain and imaging findings 10 days after positive PCR-confirmed SARS-CoV-2 infection.

Wang F, Wang H, Fan J et al., [15], in their study concluded that, mild pancreatic injury patterns in patients with COVID-19 pneumonia, may be related to direct viral involvement of the pancreas or from secondary enzyme abnormalities in the context of severe illness without substantial pancreatic injury.

CONCLUSION
SARS-CoV-2 has complex presentations because of multisystem involvement including the GI system. COVID-19 induced acute pancreatitis is a rare cause, and other common causes of acute pancreatitis must be ruled out. Our case reports, highlights the importance of considering SARS-CoV-2 as a new aetiological agent of acute viral pancreatitis. This article not only serves to exemplify the association between SARS CoV-2 and acute pancreatitis but also highlights the need for a high index of clinical suspicion for acute pancreatitis in patients with significant inflammatory response and abdominal pain with a COVID positive status. Further studies and larger series are needed to establish the clinical significance of pancreatic injury in COVID-19 patients.

REFERENCES